TY - JOUR
KW - Buprenorphine/therapeutic use
KW - Clinical Trials as Topic
KW - Cooperative Behavior
KW - Data Collection
KW - Evidence-Based Medicine
KW - Follow-Up Studies
KW - Humans
KW - Narcotic Antagonists/therapeutic use
KW - Opioid-Related Disorders/rehabilitation
KW - Substance Abuse Treatment Centers/methods/trends
KW - United States
AU - H. K. Knudsen
AU - A. J. Abraham
AU - J. A. Johnson
AU - P. M. Roman
A1 - 
AB - The National Drug Abuse Treatment Clinical Trials Network (CTN), a collaborative federal research initiative that brings together universities and community-based treatment programs (CTPs), has conducted multiple clinical trials of buprenorphine for opioid dependence. Part of the CTN's mission is to promote the adoption of evidence-based treatment technologies. Drawing on a data collected during face-to-face interviews with administrators from a panel of 206 CTPs, this research examines the adoption of buprenorphine over a 2-year period. These data indicated that the adoption of buprenorphine doubled between the baseline and 24-month follow-up interviews. Involvement in a buprenorphine protocol continued to be a strong predictor of adoption at the 2-year follow-up, although adoption of buprenorphine tripled among those CTPs without buprenorphine-specific protocol experience. For-profit CTPs and those offering inpatient detoxification services were more likely to adopt buprenorphine over time. A small percentage of programs discontinued using buprenorphine. These findings point to the dynamic nature of service delivery in community-based addiction treatment and the continued need for longitudinal studies of organizational change.
BT - Journal of substance abuse treatment
C5 - Opioids & Substance Use
CP - 3
CY - United States
DO - 10.1016/j.jsat.2008.12.004
IS - 3
JF - Journal of substance abuse treatment
N2 - The National Drug Abuse Treatment Clinical Trials Network (CTN), a collaborative federal research initiative that brings together universities and community-based treatment programs (CTPs), has conducted multiple clinical trials of buprenorphine for opioid dependence. Part of the CTN's mission is to promote the adoption of evidence-based treatment technologies. Drawing on a data collected during face-to-face interviews with administrators from a panel of 206 CTPs, this research examines the adoption of buprenorphine over a 2-year period. These data indicated that the adoption of buprenorphine doubled between the baseline and 24-month follow-up interviews. Involvement in a buprenorphine protocol continued to be a strong predictor of adoption at the 2-year follow-up, although adoption of buprenorphine tripled among those CTPs without buprenorphine-specific protocol experience. For-profit CTPs and those offering inpatient detoxification services were more likely to adopt buprenorphine over time. A small percentage of programs discontinued using buprenorphine. These findings point to the dynamic nature of service delivery in community-based addiction treatment and the continued need for longitudinal studies of organizational change.
PP - United States
PY - 2009
SN - 1873-6483; 0740-5472
SP - 307
EP - 312
EP - 
T1 - Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network
T2 - Journal of substance abuse treatment
TI - Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network
U1 - Opioids & Substance Use
U2 - 19577406
U3 - 10.1016/j.jsat.2008.12.004
VL - 37
VO - 1873-6483; 0740-5472
Y1 - 2009
ER -